4.8 Article Proceedings Paper

Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 205, Issue -, Pages 120-127

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2014.12.036

Keywords

Engineered nucleases; Genome silencing vs genome editing; Gene, protein and cell therapy; Viral and non-viral delivery systems

Funding

  1. National Research Foundation of Korea [2014049587]
  2. Brain Korea 21 plus program [22A20130011095]
  3. Korean Health Technology R&D project through the Ministry of Health Welfare [HI13C-1938-010014]

Ask authors/readers for more resources

Gene therapy by engineered nucleases is a genetic intervention being investigated for curing the hereditary disorders by targeting selected genes with specific nucleotides for establishment, suppression, abolishment of a function or correction of mutation. Here, we review the fast developing technology of targeted genome engineering using site specific programmable nucleases zinc finger nucleases (ZFNs), transcription activator like nucleases (TALENs) and cluster regulatory interspaced short palindromic repeat/CRISPR associated proteins (CRISPR/Cas) based RNA-guided DNA endonucleases (RGENs) and their different characteristics including pros and cons of genome modifications by these nucleases. We have further discussed different types of delivery methods to induce gene editing, novel development in genetic engineering other than nucleases and future prospects. (C) 2014 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available